Tags

Type your tag names separated by a space and hit enter

Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea.
Vaccine 2011; 29(7):1395-8V

Abstract

The 2009 influenza pandemic was caused by a novel triple-reassortant influenza A/H1N1 virus that was further recombined with a Eurasian pig flu virus. Vaccination is a key countermeasure for disease; however, little data assessing vaccine effectiveness (VE) against the pandemic H1N1 virus are available. We conducted a matched case-control study to assess effectiveness of the 2009 influenza A/H1N1 monovalent vaccine against laboratory-confirmed, medically attended influenza patients. Subjects included in the study were ≥ 10 years of age and were treated at five university hospitals in the Republic of Korea (ROK) from December 2009 through March 2010. For subjects visiting outpatient clinics with influenza-like illness (ILI), real time reverse transcription polymerase chain reaction (rRT-PCR) was used to diagnose 2009 H1N1 influenza virus infection. Subjects with positive rRT-PCR were classified as cases, while those testing negative were controls. A valid vaccination corresponded to ≥ 14 days between receiving a dose of vaccine and symptom onset. Overall, 416 ILI subjects were analyzed, and 60 (14.4%) were vaccinated with the 2009 influenza A/H1N1 monovalent vaccine. The overall VE against pandemic 2009 A/H1N1 virus illness after adjustment for age group and presence of chronic medical conditions was 73.4% (95% confidence interval [CI]=49.1-86.1%). Both vaccine formulations (unadjuvanted and MF-59 adjuvanted) showed a statistically significant VE. In conclusion, the 2009 influenza A/H1N1 monovalent vaccine was substantially protective against pandemic influenza in the ROK during the 2009-2010 season.

Authors+Show Affiliations

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

21199701

Citation

Song, Joon Young, et al. "Effectiveness of the Pandemic Influenza A/H1N1 2009 Monovalent Vaccine in Korea." Vaccine, vol. 29, no. 7, 2011, pp. 1395-8.
Song JY, Cheong HJ, Heo JY, et al. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine. 2011;29(7):1395-8.
Song, J. Y., Cheong, H. J., Heo, J. Y., Noh, J. Y., Choi, W. S., Park, D. W., ... Kim, W. J. (2011). Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine, 29(7), pp. 1395-8. doi:10.1016/j.vaccine.2010.12.050.
Song JY, et al. Effectiveness of the Pandemic Influenza A/H1N1 2009 Monovalent Vaccine in Korea. Vaccine. 2011 Feb 4;29(7):1395-8. PubMed PMID: 21199701.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. AU - Song,Joon Young, AU - Cheong,Hee Jin, AU - Heo,Jung Yeon, AU - Noh,Ji Yun, AU - Choi,Won Suk, AU - Park,Dae Won, AU - Lee,Jacob, AU - Jeong,Hye Won, AU - Kee,Sae Yoon, AU - Kim,Woo Joo, Y1 - 2011/01/01/ PY - 2010/11/02/received PY - 2010/12/13/revised PY - 2010/12/15/accepted PY - 2011/1/5/entrez PY - 2011/1/5/pubmed PY - 2011/4/26/medline SP - 1395 EP - 8 JF - Vaccine JO - Vaccine VL - 29 IS - 7 N2 - The 2009 influenza pandemic was caused by a novel triple-reassortant influenza A/H1N1 virus that was further recombined with a Eurasian pig flu virus. Vaccination is a key countermeasure for disease; however, little data assessing vaccine effectiveness (VE) against the pandemic H1N1 virus are available. We conducted a matched case-control study to assess effectiveness of the 2009 influenza A/H1N1 monovalent vaccine against laboratory-confirmed, medically attended influenza patients. Subjects included in the study were ≥ 10 years of age and were treated at five university hospitals in the Republic of Korea (ROK) from December 2009 through March 2010. For subjects visiting outpatient clinics with influenza-like illness (ILI), real time reverse transcription polymerase chain reaction (rRT-PCR) was used to diagnose 2009 H1N1 influenza virus infection. Subjects with positive rRT-PCR were classified as cases, while those testing negative were controls. A valid vaccination corresponded to ≥ 14 days between receiving a dose of vaccine and symptom onset. Overall, 416 ILI subjects were analyzed, and 60 (14.4%) were vaccinated with the 2009 influenza A/H1N1 monovalent vaccine. The overall VE against pandemic 2009 A/H1N1 virus illness after adjustment for age group and presence of chronic medical conditions was 73.4% (95% confidence interval [CI]=49.1-86.1%). Both vaccine formulations (unadjuvanted and MF-59 adjuvanted) showed a statistically significant VE. In conclusion, the 2009 influenza A/H1N1 monovalent vaccine was substantially protective against pandemic influenza in the ROK during the 2009-2010 season. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21199701/Effectiveness_of_the_pandemic_influenza_A/H1N1_2009_monovalent_vaccine_in_Korea_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)01823-2 DB - PRIME DP - Unbound Medicine ER -